Home › Insomnia › NCT07333586
Insomnia and Insulin Resistance
Insomnia, Metabolic Syndrome and Insulin Resistance
Who can join
Ages 18 to 50 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: ages 18-50 y BMI 28-45 kg/m2 Score on the Insomnia Severity Index ≥15. Exclusion Criteria: contraindications for CBT-I (mania or seizure disorder) symptoms requiring immediate attention (e.g., psychosis, suicide intent) report illicit substance use on a monthly basis (e.g., cocaine, opioids) receiving behavioral treatment for insomnia overt cardiovascular disease overt renal disease thyroid disease cancer pregnant dieting using GLP-1 agonists taking exogenous insulin
About the study
Insomnia symptoms are linked to metabolic syndrome (MetS), which includes abnormal glucose metabolism, insulin resistance (IR), and incidence of diabetes. Chronic sleep deficit is a major predictor of disease and early mortality. Further, insomnia is the most common sleep disorder in the United States. The recommended first line of treatment for insomnia is Cognitive Behavioral Therapy for Insomnia (CBT-I). CBT-I is a multidimensional treatment that targets the thoughts and behaviors that perpetuate insomnia symptoms over time. This study will explore CBT-I effects on MetS outcomes (ie. blood pressure, triglycerides, etc.) and provide preliminary evidence that CBT-I impacts IR and fasting glucose concentrations within this population.
20 subjects with insomnia will be recruited. They will be randomly assigned to either CBT-i or sleep hygiene. The intervention is 5 wks. Pre and post intervention, the investigator will have participants fill out a number of questionnaires, a daily sleep diary, 2 weeks of actigraphy measuring sleep and physical activity and there will be a single blood draw at the beginning and the end of the study.
What is being tested
- CBT-I (behavioral)
- sleep hygiene (behavioral)
Sponsor: University of Missouri-Columbia · Participants: 20 · Started: Sep 20, 2026
Contact the study team
- Jill A Kanaley, PhD · Phone: 5737722519
Official record on ClinicalTrials.gov — NCT07333586
Locations in the U.S.
| Missouri | University of Missouri, Columbia |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.